PeptideStack
5.2kquestions
20kanswers
220users

Why did two Homopeptide lots of liraglutide differ on content assay?

Asked 21 Jun 2025Modified 11 months agoViewed 5.6k times
This question was closed as primarily opinion-based.Closed 16 Jul 2025. Answers already posted are preserved; new answers are not accepted. Questions here need a factual basis on which they can be answered.
9

Concretely: Homopeptide · liraglutide.

I have two candidate explanations and no way to distinguish them.

The same procedure has worked without incident several times previously, which argues against technique.

How do I distinguish the benign explanation from the one that matters?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
EH
askedeighty_six_hours16k2721 Jun 2025

2 Answers

Sorted by votes
46

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

Mechanically, the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
OF
answeredorla_ferriter47k389 Aug 2025
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
30

Specifically, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
ID
answeredimani_dube19k2820 Aug 2025
7Worth flagging that this changed in 2025, so older answers on the site are out of date. – tobias_maartens 7 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.